Claims
- 1. A compound selected from the group consisting of compounds having the formula ##STR28## and pharmaceutically acceptable salts thereof, in which: R.sub.1 and R.sub.2 are selected from the group consisting of a hydrogen atom, a halogen atom, an alkyl group containing 1 to 4 carbon atoms, a phenyl lower alkyl group, a naphthyl lower alkyl group, a phenyl group, a naphthyl group, a hydroxyl group, a lower alkoxy group, an NH.sub.2 group, an NH-lower alkyl group, an N(lower alkyl).sub.2 group, an NH(CO-lower alkyl) group, an NH(CO-phenyl) group, an NH(CO-naphthyl) group, and an NO.sub.2 group, and a ring of 5-8 carbon atoms including both R.sub.1 and R.sub.2 ;
- R.sub.3 is selected from the group consisting of a hydrogen atom, an alkyl group containing 1 to 4 carbon atoms, a phenyl group and a naphthyl group;
- R.sub.4 is selected from the group consisting of a hydrogen atom, a lower alkyl group, a phenyl group, a naphthyl group, a phenyl lower alkyl group and a naphthyl lower alkyl group;
- R.sub.5 is an ##STR29## group in which n is an integer of from 1 to 4, R.sub.7 is selected from the group consisting of a hydrogen atom and an alkyl group containing from 1 to 4 carbon atoms, and R.sub.8 and R.sub.9 are selected from the group consisting of a hydrogen atom, a lower alkyl group, a phenyl group, a naphthyl group, a lower alkanoyl group, a phenyl lower alkanoyl group, a naphthyl lower alkanoyl group, a benzoyl group and a naphthoyl group; and
- R.sub.6 is selected from the group consisting of a hydrogen atom, a halogen atom, a lower alkyl group, a phenyl lower alkyl group, a naphthyl lower alkyl group, a phenyl group, a naphthyl group, a hydroxyl group, a lower alkoxy group, an NH.sub.2 group, an NH-lower alkyl group, an N(lower alkyl).sub.2 group, an NHCO-lower alkyl group, an NHCO-phenyl group, and NHCO-naphthyl group and an NO.sub.2 group.
- 2. A compound according to claim 1, wherein R.sub.1 and R.sub.2 are each selected from the group consisting of hydrogen, halogen and lower alkoxy, and when R.sub.1 and R.sub.2 are taken together they form a ring of 5-8 carbon atoms, R.sub.3 is selected from the group consisting of hydrogen and alkyl containing 1 to 4 carbon atoms, R.sub.4 is selected from the group consisting of hydrogen, lower alkyl, phenyl lower alkyl, and naphthyl lower alkyl, R.sub.8 and R.sub.9 are each selected from the group consisting of hydrogen and lower alkyl, and R.sub.6 is selected from the group consisting of hydrogen, halogen, lower alkyl, phenyl, naphthyl, lower alkoxy and NO.sub.2.
- 3. A compound according to claim 1, wherein R.sub.1 and R.sub.2 are the same.
- 4. A compound according to claim 1, wherein R.sub.1 and R.sub.2 are different.
- 5. A compound according to claim 1, wherein R.sub.8 and R.sub.9 are the same.
- 6. A compound according to claim 1, wherein R.sub.8 and R.sub.9 are different.
- 7. A compound according to claim 1, which contain one or more asymmetric carbon atoms, in optically active form.
- 8. A compound according to claim 1, selected from the group consisting of
- N,N-diethyl-N'-[(benzofuran-2-yl)(p-chlorophenyl) methyl]ethylenediamine and pharmaceutically acceptable salts thereof,
- N,N-diethyl-N'-[(benzofuran-2-yl)(phenyl) methyl]ethylenediamine and pharmaceutically acceptable salts thereof,
- N,N-dimethyl-N'-[(benzofuran-2-yl)(p-chlorophenyl)methyl]ethylenediamine and pharmaceutically acceptable salts thereof,
- N,N-dimethyl-N'-[(benzofuran-2-yl)(p-chlorophenyl) methyl]propylene-diamine and pharmaceutically acceptable salts thereof,
- N,N-dimethyl-N'[(benzofuran-2-yl)(phenyl) methyl]ethylenediamine and pharmaceutically acceptable salts thereof,
- N-[(benzofuran-2-yl)(p-chlorophenyl)methyl)]2-(diethylmethylammonium)ethylamine bromide and other pharmaceutically acceptable salts thereof,
- N-[(5-bromo-benzofuran-2-yl)(phenyl)methyl]-N', N'-diethylethylenediamine and pharmaceutically acceptable salts thereof,
- N-[(benzofuran-2-yl)(p-tolyl)methyl]-N',N'-diethylenediamine and pharmaceutically acceptable salts thereof,
- N,N-dimethyl-N'-[(benzofuran-2-yl)(p-fluorophenyl) methyl]ethylenediamine and pharmaceutically acceptable salts thereof,
- N,N-dimethyl-N'-[(5-bromobenzofuran-2-yl) (phenyl) methyl]ethylenediamine and pharmaceutically acceptable salts thereof, and
- N,N,N'-trimethyl-N'-[(benzofuran-2-yl) (p-chlorophenyl)methyl]ethylenediamine and pharmaceutically acceptable salts thereof.
- 9. A compound according to claim 1, wherein R.sub.1 and R.sub.2 are each selected from the group consisting of hydrogen and halogen, R.sub.3 and R.sub.4 are both hydrogen, R.sub.8 and R.sub.9 are selected from the group consisting of hydrogen and lower alkyl, and R.sub.6 is selected from the group consisting of hydrogen, halogen and lower alkyl.
- 10. A compound according to claim 1, wherein the compound is N,N-diethyl-N'-[(benzofuran-2-yl)(p-chlorophenyl) methyl]ethylenediamine dihydrochloride.
- 11. A pharmaceutical composition comprising an anti-arrhythmic, or anti-histaminic, or anti-tussive, amount of at least one compound as claimed in claim 1 as active ingredient, in association with a member selected from the group consisting of carriers and excipients.
- 12. A composition according to claim 11, in suitable form for administration by a method selected from the group consisting of oral, parenteral and rectal administration.
- 13. A composition according to claim 12, in the form of a unit dose.
- 14. A composition according to claim 11, in the form of a unit dose.
- 15. A method of treating an arrhythmic, histaminic or tussive condition, which comprises administering to a mammal suffering from such a condition a correspondingly effective amount of a composition according to claim 11.
- 16. A method of treating a tussive condition, which comprises administering to a mammal suffering from such a condition a muscle relaxant effective amount of a composition according to claim 11.
Priority Claims (1)
Number |
Date |
Country |
Kind |
9583 A/80 |
Nov 1980 |
ITX |
|
CROSS-REFERENCE TO RELATED APPLICATION
This is a continuation-in-part of copending parent application Ser. No. 253,551, filed Apr. 13, 1981 and now abandoned.
Foreign Referenced Citations (2)
Number |
Date |
Country |
4139-63 |
Feb 1963 |
ITX |
1160925 |
Aug 1969 |
GBX |
Non-Patent Literature Citations (2)
Entry |
Silvestrini et al., Arch. Int. Pharmacodyn. Ther. 1960, vol. 129, pp. 249-263. |
Ghelardoni et al., Boll., Chim. Farm., vol. 109, (1970), pp. 48-59. |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
253551 |
Apr 1981 |
|